What is BioSpecifics Technologies Price-to-Operating-Cash-Flow?
As of today (2024-04-26), BioSpecifics Technologies's share price is $88.53.
BioSpecifics Technologies's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2020 was $3.29. Hence, BioSpecifics Technologies's Price-to-Operating-Cash-Flow Ratio for today is 26.95.
The historical rank and industry rank for BioSpecifics Technologies's Price-to-Operating-Cash-Flow or its related term are showing as below:
BSTC'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.44 Med: 25.17 Max: 83.98
Current: 24.83
During the past 13 years, BioSpecifics Technologies's highest Price-to-Operating-Cash-Flow Ratio was 83.98. The lowest was 13.44. And the median was 25.17.
BioSpecifics Technologies's Cash Flow from Operations per share for the
three
months ended in Sep. 2020 was $0.22.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2020 was $3.29.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of BioSpecifics Technologies was 21.60% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 8.60% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 25.10% per year.
During the past 13 years, BioSpecifics Technologies's highest 3-Year average Operating Cash Flow per Share Growth Rate was 136.70% per year. The lowest was -57.30% per year. And the median was 13.45% per year.
BioSpecifics Technologies Price-to-Operating-Cash-Flow Historical Data
The historical data trend for BioSpecifics Technologies's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioSpecifics Technologies Price-to-Operating-Cash-Flow Chart
|
BioSpecifics Technologies Annual Data
|
|
Trend |
Dec10 |
Dec11 |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
28.69 |
24.06 |
23.05 |
24.94 |
18.18 |
|
BioSpecifics Technologies Quarterly Data
|
|
Dec15 |
Mar16 |
Jun16 |
Sep16 |
Dec16 |
Mar17 |
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
20.02 |
18.18 |
15.36 |
15.89 |
15.78 |
Competitive Comparison of BioSpecifics Technologies's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, BioSpecifics Technologies's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioSpecifics Technologies's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioSpecifics Technologies's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where BioSpecifics Technologies's Price-to-Operating-Cash-Flow falls into.
BioSpecifics Technologies Price-to-Operating-Cash-Flow Calculation
BioSpecifics Technologies's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 88.53 | / | 3.285 |
| = | 26.95 |
BioSpecifics Technologies's Share Price of today is $88.53.
BioSpecifics Technologies's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.29.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
BioSpecifics Technologies (BioSpecifics Technologies) Business Description
Traded in Other Exchanges
N/A
Address
35 Wilbur Street, Lynbrook, NY, USA, 11563
BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.
Executives
| Paul Gitman |
director |
167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040 |
| Michael Schamroth |
director |
191 MEADOWVIEW AVENUE HEWLETT NY 11557 |
| Toby Wegman |
director, 10 percent owner |
4092 BOCAIRE BLVD. BOCA RATON FL 33487 |
| Mark N Wegman |
director |
43 OVERLOOK ROAD OSSINING NY 10562 |
| Jennifer M Chao |
director |
7 PURITAN WOODS ROAD, RYE NY 10580 |
| Joseph Truitt |
director, officer: Chief Executive Officer |
C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
| Michael A. Sherman |
director |
3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906 |
| Fishman Corey N. |
director |
DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960 |
| Patrick Hutchison |
officer: Chief Financial Officer |
C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803 |
| J Kevin Buchi |
director, officer: Chief Executive Officer |
41 MOORES ROAD, FRAZER PA 19355 |
| Patrick M Caldwell |
officer: Principal Financial Officer |
C/O PROTINE DESIGN LAB 532 BELLA CALAIS WAY SAN JOSE CA 94138 |
| Jyrki Mattila |
director |
AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355 |
| Ronald Edward Law |
officer: SVP Business Development |
23733 N. LOOKOUT PT. ROAD, LAKE BARRINGTON IL 60010 |
| Thomas Wegman |
director, 10 percent owner, officer: President |
1764 BRIAR PLACE MERRICK NY 11566 |
| Estate Of Edwin H. Wegman |
10 percent owner |
4092 BOCAIRE BLVD. BOCA RATON FL 33487 |
BioSpecifics Technologies (BioSpecifics Technologies) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BSTC has been successfully added to your